Fig 1.
Identification of early- and late-type genes.
Study design for identification and validation of early-type and late-type genes in node-negative, systemically untreated, ER-positive breast cancer. The number of probe sets identified in each step is given within parentheses.
Fig 2.
Validated early- and late-type genes.
Kaplan-Meier plots representing validated late-type (A) and early-type (B) genes, for each showing one examples of one gene associated with better prognosis and one gene associated with worse prognosis. The median was used to differentiate between patients with low and high expression. Overlap between early-type and late-type genes with the previously described proliferation metagene (C). Overlap between early-type and late-type genes with genes associated with MFS in a conventional Cox model that considers the entire follow-up period (‘non-time restricted’) (D).
Table 1.
Late-type genes that predict metastasis-free survival three years after primary treatment and later.
Table 2.
Multivariate analysis of the ten late-type probe sets in the Mainz cohort.
Table 3.
Summary of known biological functions for the validated late-type genes.
Fig 3.
Validation of late-type probe sets in tamoxifen-treated cohorts.
Forest plots for the late-type probe sets that were significantly associated with prognosis in the meta-analysis of ER-positive breast cancers treated with adjuvant tamoxifen.